RAPT Therapeutics Inc
RAPT10.585USD
+0.095+0.91%
交易中 （美东）报价延迟15分钟
174.66M总市值
亏损市盈率 TTM
关于 RAPT Therapeutics Inc 公司
RAPT Therapeutics, Inc. 是一家临床阶段的免疫学生物制药公司。该公司专注于发现、开发和商业化口服小分子疗法，以满足炎症疾病和肿瘤学领域中尚未得到满足的大量需求。该公司利用其药物发现和开发引擎，开发旨在调节这些疾病背后的关键免疫反应的选择性小分子。其领先的炎症候选药物 zelnecirnon (RPT193) 和其领先的肿瘤候选药物 tivumecirnon (FLX475) 均靶向 CC 基序趋化因子受体 4 (CCR4)，这是一种可能在炎症疾病和肿瘤学中具有广泛适用性的药物靶点。其炎症候选药物 zelnecirnon 旨在选择性抑制 2 型 T 辅助细胞向炎症组织的迁移。其肿瘤候选药物 tivumecirnon 旨在选择性抑制免疫抑制调节性 T 细胞向肿瘤的迁移。
公司简介
公司代码RAPT
公司名称RAPT Therapeutics Inc
上市日期Oct 31, 2019
CEODr. Brian Wong, M.D., Ph.D.
员工数量68
证券类型Ordinary Share
年结日Oct 31
公司地址561 Eccles Ave
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94080
电话16504899000
网址https://rapt.com/
公司代码RAPT
上市日期Oct 31, 2019
CEODr. Brian Wong, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
持股股东
持股股东
占比
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
股东类型
持股股东
占比
Private Equity
22.72%
Hedge Fund
21.17%
Investment Advisor
19.56%
Venture Capital
17.98%
Investment Advisor/Hedge Fund
16.93%
Research Firm
0.60%
Individual Investor
0.44%
Bank and Trust
0.09%
Family Office
0.02%
Other
0.50%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
295
16.46M
99.56%
-1.03M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Medicxi Ventures (UK) LLP
2.79M
16.9%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.64M
9.93%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
1.64M
9.9%
-5.63K
-0.34%
Mar 31, 2025
Foresite Capital Management, LLC
1.56M
9.45%
--
--
Mar 31, 2025
RTW Investments L.P.
1.47M
8.89%
--
--
Mar 31, 2025
BVF Partners L.P.
1.15M
6.98%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
6.26%
+668.30K
+182.32%
Mar 31, 2025
Redmile Group, LLC
809.41K
4.89%
--
--
Mar 31, 2025
Deep Track Capital LP
751.42K
4.54%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
746.35K
4.51%
+599.56K
+408.45%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
Nuveen ESG Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Humankind US Stock ETF
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
SPDR S&P Biotech ETF
0%
查看更多
ProShares UltraPro Russell2000
占比0%
iShares Micro-Cap ETF
占比0%
Nuveen ESG Small-Cap ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Humankind US Stock ETF
占比0%
Invesco Dorsey Wright Healthcare Momentum ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Proshares Ultra Russell 2000
占比0%
SPDR S&P Biotech ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
